Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Company Overview

Arrowhead Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development. Lead programs target chronic hepatitis B virus (HBV) infection (ARO-HBV), alpha-1 antitrypsin deficiency (ARO-AAT), cardiovascular disease through the silencing of apolipoprotein C-III (ARO-APOC3), and pulmonary diseases such as cystic fibrosis (ARO-ENaC). Arrowhead has entered collaboration agreements and licensing partnerships with major global pharmaceutical firms to accelerate the development and potential commercialization of its RNAi candidates.

Arrowhead conducts its research and early clinical studies primarily in the United States, with clinical trial sites and regulatory interactions spanning North America, Europe and Asia. The company’s manufacturing strategy combines internal capabilities with external contract development and manufacturing organizations (CDMOs) to support both preclinical work and advancing clinical-stage assets. This hybrid model is designed to optimize scalability as programs progress toward late-stage clinical testing.

Headquartered in Pasadena, California, Arrowhead is led by Chief Executive Officer Christopher Anzalone, who has guided the company through multiple platform refinements and strategic partnerships. The executive team comprises experienced drug developers and industry veterans dedicated to harnessing RNAi to address unmet medical needs. Arrowhead continues to expand its research collaborations and invest in next-generation delivery technologies to broaden its therapeutic reach.

Key Stats

• Today's Range: $72.63 to $77.92
• 50-Day Range: $55.01 to $79.14
• 52-Week Range: $12.89 to $79.48
• Volume: 1.63 million shs
• Average Volume: 2.61 million shs
• Market Capitalization: $10.19 billion
• P/E Ratio: 47.70
• Dividend Yield: N/A
• Price Target: $84.90
• Consensus Rating: Moderate Buy

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

Arrowhead Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 532nd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 8 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Arrowhead Pharmaceuticals has a consensus price target of $84.20, representing about 14.1% upside from its current price of $73.78.

Amount of Analyst Coverage

Arrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($3.18) to ($3.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arrowhead Pharmaceuticals is 48.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.37.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arrowhead Pharmaceuticals is 48.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.72.

Price to Book Value per Share Ratio

Arrowhead Pharmaceuticals has a P/B Ratio of 20.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.90% of the float of Arrowhead Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.66.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 7.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arrowhead Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.80

News Sentiment

Arrowhead Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Arrowhead Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

8 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

6 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,326,228.00 in company stock.

Percentage Held by Insiders

3.60% of the stock of Arrowhead Pharmaceuticals is held by insiders.

Percentage Held by Institutions

62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/08/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• RBC Capital Markets Global Healthcare Conference 2026: 5/20/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARWR
• CIK: 879407
• Web: www.arrowheadpharma.com
• Phone: (626) 304-3400
• Fax: 626-304-3401
• Employees: 400
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Arrowhead Pharmaceuticals: $84.90
• High Price Target: $110.00
• Low Price Target: $17.00
• Potential Upside/Downside: +16.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.53
• Trailing P/E Ratio: 47.76
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.63 million
• Net Margins: 18.54%
• Pretax Margin: 23.37%
• Return on Equity: 35.64%
• Return on Assets: 13.61%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 3.38
• Quick Ratio: 3.38

Sales & Book Value

• Annual Sales: $829.45 million
• Price / Sales: 12.33
• Cash Flow: $0.11 per share
• Price / Cash Flow: 662.81
• Book Value: $3.64 per share
• Price / Book: 20.07

Miscellaneous

• Outstanding Shares: 140,030,000
• Free Float: 134,991,000
• Market Cap: $10.23 billion
• Optionable: Optionable
• Beta: 1.28